Status:

COMPLETED

Combination With Gemcitabine in Advanced Pancreatic Cancer

Lead Sponsor:

Bayer

Conditions:

Pancreatic Neoplasms

Eligibility:

All Genders

18-99 years

Phase:

PHASE1

PHASE2

Brief Summary

Open-label, uncontrolled, Phase I/II study to evaluate safety and efficacy of BAY86-9766 plus gemcitabine in locally advanced, unresectable or metastatic pancreatic cancer. Phase I: Dose escalation s...

Eligibility Criteria

Inclusion

  • Male or female patients ≥18 years of age
  • Histological or cytologically confirmed locally advanced, inoperable or metastatic pancreatic adenocarcinoma not amenable to curative radiotherapy or surgery
  • Patients must have at least one uni-dimensional measurable lesion by CT or MRI according to RECIST, Version 1.1
  • Resolution of all acute toxic effects of any prior local treatment to Common Terminology Criteria for Adverse Events (CTCAE) Grade \</= 1
  • Eastern Cooperative Oncology Group performance status (ECOG PS) \</= 2
  • Patient has cardiac function, within normal range, as measured by an echocardiogram

Exclusion

  • Known history of, or symptomatic metastatic brain or meningeal tumors
  • History of cardiac disease
  • Active clinically serious infections
  • Clinically significant (ie. symptomatic) peripheral vascular disease
  • Pregnant or lactating women; women of childbearing potential not employing adequate contraception
  • Use of strong inhibitors or inducers of CYP3A4
  • Prior systemic therapy for metastatic or locally advanced, unresectable pancreatic cancer, or other malignancy
  • Previous gemcitabine or 5-fluorouracil (5-FU) given concurrently as radiosensitizers to radiation therapy in adjuvant intention if given within 6 months from start of study treatment
  • Thrombotic or embolic events such within 6 months prior to start of study treatment

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2013

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT01251640

Start Date

January 1 2011

End Date

August 1 2013

Last Update

April 8 2021

Active Locations (23)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (23 locations)

1

Aurora, Colorado, United States, 80045

2

Pittsfield, Massachusetts, United States, 01201

3

Bruxelles - Brussel, Belgium, 1070

4

Bruxelles - Brussel, Belgium, 1090